April 23, 2024
DUBLIN, Ireland, April 23, 2024 – Deciphex, a Dublin-based digital pathology company, has entered into a Collaboration Agreement with Novartis to develop artificial intelligence (AI)-based approaches with potential to transform preclinical pathology assessments in drug discovery and development. The collaboration seeks to develop a suite of AI tools that streamline the pathology evaluation of toxicological and efficacy studies.
The Collaboration Agreement brings together the expertise of Deciphex and Novartis in unsupervised AI model development and will facilitate innovation in lesion detection within tissues. It will build upon Deciphex's existing intellectual property, alongside Novartis’s AI models, digital pathology databases and tools, to develop potentially cutting-edge algorithms designed to accurately identify and quantify lesions for applications in drug discovery and development.
Key objectives of the collaboration include:
- Developing a suite of AI-enabled tools tailored to detect lesions within tissues across multiple species, supporting both Good Laboratory Practice (GLP) and non-GLP studies.
- Pursuing regulatory acceptance of AI tools by adhering to the latest regulations and guidelines governing AI development processes.
- Digitizing Novartis' extensive archive of tissue slides, via Deciphex's next generation scanning services.
"We are thrilled to collaborate with Novartis in leveraging AI technology to drive innovation in preclinical research,"
said Dr. Donal O’Shea, CEO of Deciphex.
"This partnership underscores our commitment to advancing healthcare through the development of cutting-edge solutions that address critical challenges in drug development lifecycles."
"Novartis is committed to innovating AI-based approaches with potential to accelerate drug discovery and development and bring life-changing medicines to patients faster,"
said Fiona Marshall, President of Biomedical Research at Novartis.
"We are excited to collaborate with Deciphex to enhance the efficiency and accuracy of preclinical safety studies with AI, and look forward to making transformative strides in this space.”
About Deciphex
Deciphex is at the forefront of digital pathology and AI, providing innovative solutions that drive efficiencies in pathology research and diagnostics. Through technological excellence and a commitment to innovation, Deciphex aims to transform the industry, enhancing healthcare outcomes across the globe.
Contact Information
For Deciphex:
Katie Higgins
Commercial Marketing Director
katie.higgins@deciphex.com
+35312210482
DUBLIN, Ireland, April 23, 2024 – Deciphex, a Dublin-based digital pathology company, has entered into a Collaboration Agreement with Novartis to develop artificial intelligence (AI)-based approaches with potential to transform preclinical pathology assessments in drug discovery and development. The collaboration seeks to develop a suite of AI tools that streamline the pathology evaluation of toxicological and efficacy studies.
The Collaboration Agreement brings together the expertise of Deciphex and Novartis in unsupervised AI model development and will facilitate innovation in lesion detection within tissues. It will build upon Deciphex's existing intellectual property, alongside Novartis’s AI models, digital pathology databases and tools, to develop potentially cutting-edge algorithms designed to accurately identify and quantify lesions for applications in drug discovery and development.
Key objectives of the collaboration include:
- Developing a suite of AI-enabled tools tailored to detect lesions within tissues across multiple species, supporting both Good Laboratory Practice (GLP) and non-GLP studies.
- Pursuing regulatory acceptance of AI tools by adhering to the latest regulations and guidelines governing AI development processes.
- Digitizing Novartis' extensive archive of tissue slides, via Deciphex's next generation scanning services.
"We are thrilled to collaborate with Novartis in leveraging AI technology to drive innovation in preclinical research,"
said Dr. Donal O’Shea, CEO of Deciphex.
"This partnership underscores our commitment to advancing healthcare through the development of cutting-edge solutions that address critical challenges in drug development lifecycles."
"Novartis is committed to innovating AI-based approaches with potential to accelerate drug discovery and development and bring life-changing medicines to patients faster,"
said Fiona Marshall, President of Biomedical Research at Novartis.
"We are excited to collaborate with Deciphex to enhance the efficiency and accuracy of preclinical safety studies with AI, and look forward to making transformative strides in this space.”
About Deciphex
Deciphex is at the forefront of digital pathology and AI, providing innovative solutions that drive efficiencies in pathology research and diagnostics. Through technological excellence and a commitment to innovation, Deciphex aims to transform the industry, enhancing healthcare outcomes across the globe.
Contact Information
For Deciphex:
Katie Higgins
Commercial Marketing Director
katie.higgins@deciphex.com
+35312210482
Follow us
Ireland
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin D11 KXN4
